Antibe Therapeutics Inc(Pre-Merger) T.ATE

RE:RE:Bio - Europe

[MrMugsy]

In a way we do ... this is me guessing again ...

We know that negotiations are underway but we don't know the details (but we do know the value of the drugs and the value of having those drugs to either become a player or to defend your market).

We know they are going to the TSX and then to a US exchange - I would still bet we go to the TSX this year but we can't say the same for the US.

We know the market will quickly outpace the $16B that is initially targetted.

We also know that a discovery program is underway.  I think this is in line with the supplemental patent program that is also underway.  I am going to use everything we know to date to say this is all related to bottlebrush polymer design and what a more efficient drug design can do for Aspirin and H2S.  Once this is know - pass or fail -  we know about the future potential for 346 and 352 with bottlebrush.

If bottlebrush passes wtih Aspirin, we likely have a patent that extends our lead past 2040, making the entire platform that much more valuable.  Why does this matter?  It makes the first drug and the whole company more valuable during negotiations.

So, I hope we get updates on the discovery program and the supplemental patent program to improve our DCF further and to bring more comfort to our potential partners.  I hope we still get Phase 3 enabling toxicity results in 2020 to help the partnering discussions along.

What allows for all of this to happen now?  Our strong cash position.  That's why it made sense to go to market when we did.

Depending how this rolls out may determine when and how we go to other exchanges.

Using everything we know to date along with the last presentation to put these ideas together in a best-guess status for Antibe. 

Warning ... I could be wrong.